Telomeres and telomerase as targets for anticancer drug development
- PMID: 16469501
- DOI: 10.1016/j.critrevonc.2005.08.007
Telomeres and telomerase as targets for anticancer drug development
Abstract
In most human cancers, the telomere erosion problem has been bypassed through the activation of a telomere maintenance system (usually activation of telomerase). Therefore, telomere and telomerase are attractive targets for anti-cancer therapeutic interventions. Here, we review a large panel of strategies that have been explored to date, from small inhibitors of the catalytic sub-unit of telomerase to anti-telomerase immunotherapy and gene therapy. The many positive results that are reported from anti-telomere/telomerase assays suggest a prudent optimism for a possible clinical application in a close future. However, we discuss some of the main limits for these approaches of antitumour drug development and why significant work remains before a clinically useful drug can be proposed to patients.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources